- Roche is investing more than $3.2 billion in a 433-ft R&D center at an existing site in Basel.
- The site will be comprised of four new high-rise towers, surrounded by low-rise buildings. Roche took considerations such as livability and view line into account when constructing the plans.
- Eventually, more than 9,000 of Roche's Basel-based employees will be based at this site.
This $3.2 billion investment is designed to accomplish a lot of disparate, yet related, goals. In addition to R&D buildings, which will include an in vivo research facility, the facility will provide an enormous amount of office space for employees. And as this vision comes into shape with a targeted completion date of 2022, all workers in Basel will be able to work at one site, obviating the need to build over green zones.